A5015675649- Molecular Biology Techniques and Applications
- Cancer Genomics and Diagnostics
- Gene expression and cancer classification
- Single-cell and spatial transcriptomics
- PI3K/AKT/mTOR signaling in cancer
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- RNA Interference and Gene Delivery
- Protein Tyrosine Phosphatases
- Circular RNAs in diseases
- Extracellular vesicles in disease
- Cancer-related Molecular Pathways
- Global Cancer Incidence and Screening
- RNA modifications and cancer
- Cancer Cells and Metastasis
- RNA Research and Splicing
- Advanced Biosensing Techniques and Applications
- Cutaneous Melanoma Detection and Management
- FOXO transcription factor regulation
- Chronic Lymphocytic Leukemia Research
- Thyroid Cancer Diagnosis and Treatment
- Clinical practice guidelines implementation
- Brain Metastases and Treatment
- Advanced Breast Cancer Therapies
- 14-3-3 protein interactions
Joint Research Centre
2024
Mater Dei Hospital
2022-2023
University of Malta
2013-2022
ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions extracellular vesicles (EVs), collective term covering various subtypes cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, many other names. However, specific issues arise when working with these entities, whose size amount often make them difficult to obtain as relatively...
// Rosa Drago-Ferrante 1 , Francesca Pentimalli 2 Daniela Carlisi 3 Anna De Blasio Christian Saliba 4 Shawn Baldacchino 5 James Degaetano 6 Joseph Debono 7 Gordon Caruana-Dingli Godfrey Grech Scerri 6, 8 Giovanni Tesoriere 9, 11 Antonio Giordano 10 Renza Vento 1, Riccardo Di Fiore Laboratory of Biochemistry, Department Biological, Chemical and Pharmaceutical Sciences Technologies, University Palermo, Polyclinic, Italy Oncology Research Center Mercogliano (CROM), Istituto Nazionale per lo...
Abstract The present study shows that nuclear factor erythroid 2‐related 2 (NRF2) and miR‐29b‐1‐5p are two opposite forces which could regulate the fate of MDA‐MB‐231 cells, most studied triple‐negative breast cancer (TNBC) cell line. We show NRF2 activation stimulates growth markedly reduces reactive oxygen species (ROS) generation, whereas overexpression increases ROS generation proliferation. Moreover, downregulates expression, decreases p‐AKT p‐NRF2. Furthermore, induces both inhibition...
The most commonly used biomarkers to predict the response of breast cancer patients therapy are oestrogen receptor (ER), progesterone (PgR), and human epidermal growth factor 2 (HER2). Patients positive for these eligible specific therapies such as endocrine treatment in event ER PgR positivity, monoclonal antibody, trastuzumab, case HER2-positive patients. who negative three biomarkers, so-called triple negatives, however, derive little benefit from associated with a worse prognosis....
Abstract Triple‐negative breast cancer (TNBC) is a form of BC characterized by high aggressiveness and therapy resistance probably determined stem cells. MCL1 an antiapoptotic Bcl‐2 family member that could limit the efficacy anticancer agents as recombinant human tumor necrosis factor related apoptosis‐inducing ligand (rh‐TRAIL). Here, we investigated expression in TNBC tissues We found differentially expressed (upregulated or downregulated) tissues. Furthermore, comparison to mammary...
Nucleic acid degradation in archival tissue, tumor heterogeneity, and a lack of fresh frozen tissue specimens can negatively impact cancer diagnostic services pathology laboratories worldwide. Gene amplification expression testing using material or that requires transportation to servicing laboratories, needs more robust accurate test adapted current clinical workflows. Our research team optimized the use Invitrogen™ QuantiGene™ Plex Assay (Thermo Fisher Scientific) quantify RNA branched-DNA...
Diagnosing thyroid carcinoma is not always easy on basic haemtoxylin and eosin staining since nuclear features are inconsistent controversial. In view of this, studies the role immunohistochemical markers in diagnosis malignant necessary. Proposed for papillary cancer include Hector Battifora mesothelial-1 (HBME-1), Galectin-3 (Gal-3) which have been studied this project. Immunohistochemical fifty-eight formalin-fixed paraffin embedded surgically removed tissue from years 2008 2013 was...
The use of archival formalin-fixed paraffin-embedded (FFPE) material to analyse gene expression is limited by the low quality extracted RNA.In this paper, we utilised an RNA based assay quantify luminal and basal markers, together with ERBB2 probes, in FFPE tissue from 2009 2010, all which had clinical therapeutic information more than 5 years.Receptor status patients was characterised using QuantiGene® Plex 100% concordance immunohistochemical (IHC) fluorescence situ hybridisation (FISH)...
Nucleic acid degradation in archival tissue, tumor heterogeneity, and a lack of fresh frozen tissue specimens can negatively impact cancer diagnostic services pathology laboratories worldwide. Gene amplification expression testing using material or that requires transportation to servicing laboratories, needs more robust accurate test adapted current clinical workflows. Our research team optimized the use Invitrogen™ QuantiGene™ Plex Assay (Thermo Fisher Scientific) quantify RNA branched-DNA...
CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade therapeutic resistance. drives oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, promoting epithelial-to-mesenchymal transition, although further biological mechanisms for are yet to be defined. expression was studied by immunohistochemistry in oestrogen receptor–positive primary breast cancers (n = 250) obtained from the Leeds Tissue...
The characterisation of the molecular mechanism disease allows classification patients into subtypes and potentially identifies specific targets for therapeutic intervention. Tyrosine kinase mutations are central to targeted therapy. Investigation deregulation within particular patient groups, has led identification mutant tyrosine kinases associated with progression therapy modulation. Biomarker-specific therapies emerged, taking a leading role in guided-therapy. extensive use inhibitors...